These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 29740793)

  • 1. Immune checkpoint receptors: homeostatic regulators of immunity.
    Riva A; Chokshi S
    Hepatol Int; 2018 May; 12(3):223-236. PubMed ID: 29740793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint inhibitors in hematological malignancies.
    Ok CY; Young KH
    J Hematol Oncol; 2017 May; 10(1):103. PubMed ID: 28482851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.
    Shah N; Sandigursky S; Mor A
    Bull Hosp Jt Dis (2013); 2017 May; 75(3):155-163. PubMed ID: 28902599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors for cancer treatment.
    Park J; Kwon M; Shin EC
    Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection.
    Sperk M; Domselaar RV; Neogi U
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the checkpoint blockade in lung cancer immunotherapy.
    Dal Bello MG; Alama A; Coco S; Vanni I; Grossi F
    Drug Discov Today; 2017 Aug; 22(8):1266-1273. PubMed ID: 28600190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The blockade of immune checkpoints in cancer immunotherapy.
    Pardoll DM
    Nat Rev Cancer; 2012 Mar; 12(4):252-64. PubMed ID: 22437870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance.
    Ye B; Liu X; Li X; Kong H; Tian L; Chen Y
    Cell Death Dis; 2015 Mar; 6(3):e1694. PubMed ID: 25789969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy.
    Lee J; Han Y; Wang W; Jo H; Kim H; Kim S; Yang KM; Kim SJ; Dhanasekaran DN; Song YS
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Not All Immune Checkpoints Are Created Equal.
    De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
    Front Immunol; 2018; 9():1909. PubMed ID: 30233564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of immune checkpoint regulators and potential role of soluble TIM-3 and LAG-3 in male patients with alcohol-associated liver disease.
    Fadriquela A; Kim CS; Lee KJ; Kang SH; Lee JH
    Alcohol; 2022 Feb; 98():9-17. PubMed ID: 34695559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The biology of PD1 and CTLA-4 as immunotherapeutic targets and the issue of biomarkers].
    Dieu-Nosjean MC; Caux C
    Med Sci (Paris); 2019 Dec; 35(12):957-965. PubMed ID: 31903900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highlights on immune checkpoint inhibitors in non-small cell lung cancer.
    Shen M; Ren X
    Tumour Biol; 2017 Mar; 39(3):1010428317695013. PubMed ID: 28349816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors: Therapeutic Tools for Breast Cancer.
    Su M; Huang CX; Dai AP
    Asian Pac J Cancer Prev; 2016; 17(3):905-10. PubMed ID: 27039716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
    Dempke WCM; Fenchel K; Uciechowski P; Dale SP
    Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.